Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cidoxepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidoxepin SCHEMBL29493441 | 1.00 | HTR2B (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL31349647 | 1.00 | HTR2B (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL28054 | 1.00 | HTR2B (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| E-Doxepin SCHEMBL116895 | 1.00 | HTR2B (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Cidoxepin SCHEMBL29368454 | 0.99 | ALDH1A1 (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL5655381 | 0.99 | HTR2B (0.97) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL1281891 | 0.99 | ALDH1A1 (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL29359800 | 0.99 | ALDH1A1 (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Doxepin SCHEMBL41532 | 0.99 | ALDH1A1 (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 | |
| Cidoxepin SCHEMBL124597 | 0.99 | ALDH1A1 (1.00) | HTR2BHRH1KCNH2ALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | claimed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | claimed |
| WO-2023282544-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | 국립암센터 | 2023-01-12 | — | — | WO | claimed |
| US-20220401383-A1 | Cannabidiol and/or Cobicistat Combination Drug Therapy | SHINKEI THERAPEUTICS INC (US) | 2022-12-22 | — | — | US | claimed |
| EP-4061346-A1 | CANNABIDIOL AND/OR COBICISTAT COMBINATION DRUG THERAPY | Shinkei Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| CN-115003289-A | Cannabidiol and/or cobicistat combination drug therapy | 新凯治疗有限公司 | 2022-09-02 | — | — | CN | claimed |
| WO-2021102428-A1 | CANNABIDIOL AND/OR COBICISTAT COMBINATION DRUG THERAPY | SHINKEI THERAPEUTICS, INC. (US) | 2021-05-27 | — | — | WO | claimed |
| US-20200390698-A1 | URETHRAL DEVICES FOR TREATMENT OF PATHOLOGICAL UROLOGICAL CONDITIONS | INURA MEDICAL AG (CH) | 2020-12-17 | — | — | US | claimed |
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | MENLO THERAPEUTICS INC. (US) | 2019-07-18 | — | — | US | claimed |
| EP-3478283-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | Menlo Therapeutics Inc. (US) | 2019-05-08 | — | — | EP | claimed |
| WO-2017134094-A1 | URETHRAL DEVICES FOR TREATMENT OF PATHOLOGICAL UROLOGICAL CONDITIONS | INURA MEDICAL AG (CH) | 2017-08-10 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20110021499-A1 | URETHRAL SUPPOSITORIES FOR OVERACTIVE BLADDER | FRANKLIN AMIE ELLEN | 2011-01-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2008103442-A1 | URETHRAL SUPPOSITORIES FOR OVERACTIVE BLADDER | URIGEN PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216779-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS | BDKRB2, BDKRB1, PBK | HRH1 122/4885SLC6A2 108/4885HTR2B 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.